Last updated on September 2018

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers


Brief description of study

This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab, may be able to shrink tumors. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with squamous cell lung cancer.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To compare overall survival (OS) in patients with advanced stage refractory squamous cell carcinoma (SCCA) of the lung randomized to nivolumab plus ipilimumab versus nivolumab.

SECONDARY OBJECTIVES:

I. To compare investigator-assessed progression-free survival (IA-PFS) in patients with advanced stage refractory SCCA of the lung randomized to nivolumab plus ipilimumab versus nivolumab.

II. To compare the response rates (confirmed and unconfirmed, complete and partial) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 among patients randomized to receive nivolumab plus ipilimumab versus nivolumab.

III. To compare the response rates (confirmed only, complete and partial) per RECIST 1.1 among patients randomized to receive nivolumab plus ipilimumab versus nivolumab.

IV. To evaluate the frequency and severity of toxicities associated with nivolumab plus ipilimumab versus nivolumab.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To evaluate if there is a differential treatment effect on OS, IA-PFS, and response by tumor programmed death-ligand 1 (PD-L1) expression status.

II. To examine patient reported outcomes by treatment arm.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment but prior to disease progression, patients are followed up every 3 months for 1 year and then every 6 months for up to 3 years. After disease progression, patients are followed up every 6 months for 2 years and at end of year 3 after sub-study registration.

Clinical Study Identifier: NCT02785952

Find a site near you

Start Over

Mercy Health Saint Mary's

Grand Rapids, MI United States
  Connect »

Hardin Memorial Hospital

Elizabethtown, KY United States
  Connect »

MetroHealth Medical Center

Cleveland, OH United States
  Connect »

Frederick Memorial Hospital

Frederick, MD United States
  Connect »

Assarian Cancer Center

Novi, MI United States
  Connect »

Katmai Oncology Group

Anchorage, AK United States
  Connect »

Rapid City Regional Hospital

Rapid City, SD United States
  Connect »

Bryn Mawr Hospital

Bryn Mawr, PA United States
  Connect »

Mary Imogene Bassett Hospital

Cooperstown, NY United States
  Connect »

Roper Hospital

Charleston, SC United States
  Connect »

Carle Cancer Center

Urbana, IL United States
  Connect »

University of Virginia Cancer Center

Charlottesville, VA United States
  Connect »

Kootenai Cancer Center

Post Falls, ID United States
  Connect »

Adena Regional Medical Center

Chillicothe, OH United States
  Connect »

Baystate Medical Center

Springfield, MA United States
  Connect »

Mercy Hospital

Coon Rapids, MN United States
  Connect »

Lowell General Hospital

Lowell, MA United States
  Connect »

Sinai Hospital of Baltimore

Baltimore, MD United States
  Connect »

Meharry Medical College

Nashville, TN United States
  Connect »

Boulder Community Hospital

Boulder, CO United States
  Connect »

Reid Health

Richmond, IN United States
  Connect »

Feather River Cancer Center

Paradise, CA United States
  Connect »

Mills-Peninsula Medical Center

Burlingame, CA United States
  Connect »